Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of drug products.
Inspection Record
PReye LLC — FDA 483 Findings
Inspectors Brittny C CargoThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
There is no quality control unit.
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.
The identity of each component of a drug product is not verified by conducting at least one test to verify the identity, using specific identity tests if they exist.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- SURETEC INNOVATIONS LLC2026-03-05 · US FDASimilar to finding 2 There is no quality control unit.
- Brassica Pharma Pvt Ltd.2024-01-19 · US FDASimilar to finding 1 Separate or defined ai·eas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of diu g products.
- Bello Bio LLC2025-12-16 · US FDASimilar to finding 2 There is no quality control unit.
- Clarcon Biological Chemistry Laboratory2015-07-24 · US FDASimilar to finding 2 There is no quality control unit.
- TAILSTORM HEALTH INC2026-08-28 · US FDASimilar to finding 1 Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of drug products.
A record as of the US FDA document published on 2026-10-23. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.